Hematology-American Society of Hematology Education Program

Papers
(The TQCC of Hematology-American Society of Hematology Education Program is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Your chemo is no good here: management of high-risk MCL85
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?73
Labor and delivery: DIC, HELLP, preeclampsia54
Neurological manifestations of MGUS51
Inpatient recognition and management of HLH41
On the horizon: upcoming new agents for the management of ITP35
The varieties of therapeutic experience: navigating treatment options for patients with PNH32
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment28
Challenges and opportunities in the long-term management of immune-mediated TTP27
Recognizing, defining, and managing CAR-T hematologic toxicities26
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?26
Bispecific antibody therapies24
Mastocytosis demystified24
Anticoagulation at the end of life: whether, when, and how to treat24
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma23
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient22
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL22
Where do immunotherapies stand in management of acute leukemia in adults?21
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma21
Has PD-1 blockade changed the standard of care for cHL?20
New therapies in hemophilia: extend the half-life, mimic, or rebalance?20
Fitness and frailty in myeloma19
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?19
Divergent paths: management of early relapsed follicular lymphoma19
How to assess hemostasis in patients with severe liver disease18
MGCS: where do we stand today?18
Selecting initial therapy in CLL17
New approaches to tackle cytopenic myelofibrosis17
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL17
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia17
Donor selection, graft engineering, and dosing oh my!16
BV and beyond: how to incorporate novel agents into PTCL management15
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease15
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores15
Optimizing outcomes in secondary AML15
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?15
How to manage hemostasis in patients with liver disease during interventions15
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies15
Troubleshooting heparin resistance15
Incorporating novel agents into frontline treatment of Hodgkin lymphoma15
What's new in hereditary hemorrhagic telangiectasia?14
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity14
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?14
Hematology 2022—what is complete HLA match in 2022?14
Management of TKI-resistant chronic phase CML14
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?14
How to diagnose and manage antiphospholipid syndrome14
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation14
Demystifying autoimmune HIT: what it is, when to test, and how to treat13
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 20213
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL13
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma13
Consumptive coagulopathy in the ICU13
Special considerations in GI bleeding in VWD patients12
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies12
Approaches to management of HIT in complex scenarios, including cardiac surgery12
Management of marginal zone lymphomas12
Atypical CML: diagnosis and treatment12
Management of limited-stage Hodgkin lymphoma12
Transplant in AML with measurable residual disease: proceed or defer?11
Organ function indications and potential improvements following curative therapy for sickle cell disease11
Pregnancy management for patients with bleeding disorders11
Thrombosis questions from the inpatient wards11
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?11
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing11
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy11
Management of autoimmune hemolytic anemia11
CNS prophylaxis in aggressive B-cell lymphoma11
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms10
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?10
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment10
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease10
Treatment of VTE in the thrombocytopenic cancer patient10
Nontransplant treatment approaches for myeloid neoplasm with mutated TP5310
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment10
Pegylated interferon: the who, why, and how10
Cytoreduction for ET and PV: who, what, when, and how?10
Alloimmunization and hyperhemolysis in sickle cell disease10
Future directions in transplantation for aplastic anemia9
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma9
Ph− ALL: immunotherapy in upfront treatment9
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?9
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?9
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS9
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes9
Thrombocytopenia in pregnancy9
Clinical manifestations of telomere biology disorders in adults9
Monoclonal gammopathy of renal significance from a hematologic perspective9
What is the ideal approach—doublet, triplet, or quadruplet(s)?9
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS9
POEMS syndrome: diagnosis, treatments, and outcomes9
What makes a pediatric or young adult patient an appropriate transplant candidate?9
Next-generation therapy for lower-risk MDS9
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era9
Managing pregnancy in patients with sickle cell disease from a transfusion perspective9
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax8
Should we use bisphosphonates to treat bone complications in sickle cell disease?8
Managing side effects: guidance for use of immunotherapies in multiple myeloma8
Managing patients with a history of arterial disease and new venous thromboembolism8
Approach to the patient with suspected hypereosinophilic syndrome8
What to know about rare B-cell malignancies in 20258
Sequencing bispecific antibodies and CAR T cells for FL8
The role of stem cell transplant (auto and allo) in PTCL and CTCL8
0.099167108535767